Physician profile
Simran Kaur
NPI 1649406349
$659.91
in general payments reported to CMS, 2019-2025
10 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $18.98 · 2023: $149 · 2024: $265 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $144.98 | 2023-2024 | Repatha, Otezla |
| Abbvie INC. | $124.28 | 2024 | |
| Lilly USA, LLC | $107.10 | 2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.45 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $79.86 | 2021 | |
| Glaxosmithkline, LLC. | $28.14 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $22.09 | 2023 | Firdapse |
| Janssen Pharmaceuticals, INC | $18.98 | 2022 | |
| Novo Nordisk INC | $15.45 | 2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simran Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.